XML 28 R5.htm IDEA: XBRL DOCUMENT v3.25.4
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Revenues:      
Total revenue $ 75,128 $ 28,833 $ 38,025
Operating expenses:      
Research and development [1] 186,829 167,259 175,658
Sales, general and administrative [1] 83,231 85,490 75,179
Depreciation, amortization, and impairment 22,171 90,850 24,395
Total operating expenses 292,231 343,599 275,232
Loss from operations (217,103) (314,766) (237,207)
Other (income) expense:      
Interest income (28,329) (38,473) (42,247)
Grants and incentives (13,890) (13,620) (14,155)
Other (Note 15) 2,711 (62,278) (6,776)
Total other income (39,508) (114,371) (63,178)
Loss before income tax (177,595) (200,395) (174,029)
Income tax recovery (31,183) (37,538) (27,631)
Net loss (146,412) (162,857) (146,398)
Foreign currency translation adjustment 144 (2,658) (329)
Comprehensive loss $ (146,268) $ (165,515) $ (146,727)
Net loss per share      
Basic (in dollars per share) $ (0.49) $ (0.55) $ (0.51)
Diluted (in dollars per share) $ (0.49) $ (0.55) $ (0.51)
Weighted-average common shares outstanding      
Basic (in shares) 298,707,082 294,327,532 289,166,486
Diluted (in shares) 298,707,082 294,327,532 289,166,486
Research fees      
Revenues:      
Total revenue $ 27,208 $ 26,284 $ 35,556
Milestone payments      
Revenues:      
Total revenue 1,000 1,500 1,500
Licensing and royalty revenue      
Revenues:      
Total revenue $ 46,920 $ 1,049 $ 969
[1] Exclusive of depreciation, amortization, and impairment